Biomarker-Driven Lung Cancer

Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.

A phase 1a trial of GDC-6036 showed encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.

Ociperlimab plus tislelizumab revealed promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer.

Tremelimumab plus durvalumab and chemotherapy displayed improvements in clinical and survival benefit in patients with PD-L1 negative metastatic non–small cell lung cancer.

Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.

Cary Gross, MD, discusses the results of a retrospective study of patients with advanced non-small cell lung cancer that showed an association between Medicaid insurance, rates of biomarker testing, and patient outcomes.

A pre-NDA meeting with the FDA discussed planned patient follow-up for patients with ROS1+ advanced non-small cell lung cancer in cohorts of the ongoing TRIDENT-1 study of repotrectinib.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, addresses remaining clinical questions for the treatment of MET fusion positive patients with non–small cell lung cancer.

A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.

Nathan A. Pennell, MD, PhD, discusses the study design and goals of an ongoing phase 1 trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.

Nathan Pennell, MD, PhD, discusses a first-in-human trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

Combination of toripalimab and chemotherapy in the frontline setting shows survival benefit in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.

In patients enrolled in the phase 1b portion of the KRYSTAL-1 trial who received adagrasib, the intracranial objective response rate was 32%.

Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.

Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Andreas Saltos, MD, discussed treatment options for EGFR and KRAS-mutated NSCLC, and the investigational use of binimetinib to treat these tumors.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discussed the prevalence of MET fusions in patients with non-small cell lung cancer and the impact of identifying them when making treatment decisions.

In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.

Lyudmila Bazhenova, MD, discusses targeted therapies for patients with HER2-mutated non–small cell lung cancer.

At the upcoming 23rd Annual International Lung Cancer Congress®, Solange Peters, MD, PhD will be giving two presentation around relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged non–small cell lung cancer.

With results offering promising efficacy data and a manageable safety profile, unecritinib can be regarded as a new first-line treatment option.

Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.

In an interview with Targeted Oncology, Marc Ladanyi, MD, discussed pooled data of larotrectinib in patients with NTRK fusion-positive cancers and how variability in NTRK gene fusions impacts outcomes.

In an interview with Targeted Oncology™, Yonina R. Murciano-Goroff, MD, MSc, DPhil, discussed how MET fusions impact patients with NSCLC and the issue of resistance to targeted therapies that treat MET fusion-positive disease.

During a case-based roundtable event, Estelamari Rodriguez, MD, MPH, discussed the case of a patient who had lung cancer with 3 brain metastases and a RET fusion.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with MET-mutated non–small cell lung cancer.

In patients with non–small cell lung cancer who harbor a MET exon 14 skipping mutation, treatment with SCC244 appears efficacious.

Sotorasib continues to wow in the phase 1/2 CodeBreaK 100 trial of patients with KRAS G12C–mutant non–small cell lung cancer.